The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.i

Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

Publications

Randall JM, Bharne AA, Bazhenova LA

Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer.

Journal of thoracic disease 2013 Apr;5;E53-7 — 2013 Apr — E53-7

Potolidis E, Mandros C

Carboplatin-induced hypersensitivity reaction.

Case reports in oncology 2012 Jan;5;141-2 — 2012 Jan — 141-2

Williams L, Markman M

Hypersensitivity following Retreatment with Carboplatin a Decade after Completion of Primary Platinum-Based Chemotherapy.

Case reports in oncology 2009 Feb 20;2;20-23 — 2009 Feb 20 — 20-23

Abe A, Ikawa H, Ikawa S

Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer.

The journal of medical investigation : JMI 2010 Feb;57;163-7 — 2010 Feb — 163-7

Broome CB, Schiff RI, Friedman HS

Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions.

Medical and pediatric oncology 1996 Feb;26;105-10 — 1996 Feb — 105-10

Weidmann B, Mülleneisen N, Bojko P, Niederle N

Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management.

Cancer 1994 Apr 15;73;2218-22 — 1994 Apr 15 — 2218-22